Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Other financing activities (2017 - 2026)

Conmed filings provide 16 years of Other financing activities readings, the most recent being $828000.0 for Q1 2026.

  • On a quarterly basis, Other financing activities rose 278.45% to $828000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $4.2 million, a 81.97% increase, with the full-year FY2025 number at $2.9 million, up 2.26% from a year prior.
  • Other financing activities hit $828000.0 in Q1 2026 for Conmed, down from $2.9 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $15.4 million in Q3 2022 to a low of -$13.4 million in Q4 2022.
  • Median Other financing activities over the past 5 years was $916000.0 (2023), compared with a mean of $2.1 million.
  • Biggest five-year swings in Other financing activities: skyrocketed 3494.6% in 2023 and later tumbled 792.54% in 2025.
  • Conmed's Other financing activities stood at -$13.4 million in 2022, then surged by 109.36% to $1.2 million in 2023, then soared by 126.64% to $2.8 million in 2024, then increased by 1.59% to $2.9 million in 2025, then crashed by 71.23% to $828000.0 in 2026.
  • The last three reported values for Other financing activities were $828000.0 (Q1 2026), $2.9 million (Q3 2025), and $483000.0 (Q2 2025) per Business Quant data.